Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
Paused · Phase 1
Conditions studied: Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
In brief
This study will use brain Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) and an investigational radioactive drug called \[Zr-89\]oxine to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will be used to visualize labeled white blood cells and determine if they enter the central nervous system in conditions associated with brain inflammation (also called neuroinflammation). By better understanding the role of neuroinflammation in fibromyalgia, chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better diagnose and treat patients in the future.
Key facts
- Study ID
- NCT03807973
- Run by
- University of Alabama at Birmingham
- People needed
- 120
- Starts
- 2021-10-05
- Expected to finish
- 2028-10-01
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- 18 to 65 years of age 2.Healthy volunteer OR
- Clinical diagnosis of Multiple Sclerosis (MS) OR
- Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR
- Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome
You may not qualify if…
- Contraindication to MRI
- Pregnancy
- Lactation
- Individuals who are unable to participate in the imaging portion due to severity of their medical condition
- Chronic infectious disease (e.g. HIV, HCV)
- Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation
- Diagnosis of cancer, including leukemia
- Blood or blood clotting disorder
- Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary
- Positive urine pregnancy test day of procedure or a serum pregnancy test within 48 hours prior to the administration of Zirconium-89 Oxinate-4-labeled leukocytes
- Currently enrolled in a clinical trial utilizing experimental therapies
- Contraindication to gadolinium based contrast agents
Where it is running
- UAB — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.